Baricitinib e il rischio di malattia polmonare interstiziale incidente: un caso clinico descrittivo da studi clinici

Rheumatol Ther. 2021 Jun 28. DOI: 10.1007/s40744-021-00332-w

Findings from a descriptive clinical case report from clinical trials show that patients with RA, treated with baricitinib, are at low risk to developing non-infectious interstitial lung disease (ILD) during treatment.Salvarani, et al. used a descriptive, multicentric, retrospective cohort study of eight randomised trials and one long-term extension study to estimate the number of incident ILD cases reported. Their findings showed that the risk of developing non-infectious ILD during baricitinib treatment was similar to that observed with other JAK inhibitors.

Keywords:


Publication thumbnail: Baricitinib e il rischio di malattia polmonare interstiziale incidente: un caso clinico descrittivo da studi clinici
LinkedIn